Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis

Human Immunology

Volumn 71, Issue 2, 2010, Pages 212-219

  Bonagura, Vincent R ^a,b,c   Du, Zeying ^e   Ashouri, Elham ^e   Luo, Lihui ^e   Hatam, Lynda J ^a   DeVoti, James A ^a   Rosenthal, David W ^a,b,c   Steinberg, Bettie M ^a,c,d   Abramson, Allan L ^a,d   Gjertson, David W ^e   Reed, Elaine F ^e   Rajalingam, Raja ^e  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^c Long Island Jewish Medical Center ^*  (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HLA association; Human papillomaviruses 6 and 11; Killer cell immunoglobulin like receptors; Natural killer cells; Recurrent respiratory papillomatosis

Indexed keywords

CD57 ANTIGEN; DNA; GENOMIC DNA; HLA ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; NATURAL KILLER CELL; PAPILLOMATOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RECURRENT DISEASE; RESPIRATORY PAPILLOMATOSIS;

CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMAN PAPILLOMAVIRUS 6; HUMANS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; PHENOTYPE; RECEPTORS, KIR; RECEPTORS, KIR3DS1; RECURRENCE; TUMOR VIRUS INFECTIONS;

EID: 74849090936     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.10.009     Document Type: Article

References (50)

1. Derkay C.S., and Wiatrak B. Recurrent respiratory papillomatosis: A review. Laryngoscope 118 (2008) 1236-1247
2. Auborn K.J., Wang H., Vaccariello M.A., and Taichman L.B. Kinetics of HPV11 DNA replication after infection of keratinocytes with virions. Virus Res 43 (1996) 85-90
3. Bonagura V.R., Hatam L., DeVoti J., Zeng F., and Steinberg B.M. Recurrent respiratory papillomatosis: Altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin Immunol 93 (1999) 302-311
4. DeVoti J.A., Steinberg B.M., Rosenthal D.W., Hatam L., Vambutas A., Abramson A.L., et al. Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin Diagn Lab Immunol 11 (2004) 538-547
5. Gelder C.M., Williams O.M., Hart K.W., Wall S., Williams G., Ingrams D., et al. HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis. J Virol 77 (2003) 1927-1939
6. Bonagura V.R., Vambutas A., DeVoti J.A., Rosenthal D.W., Steinberg B.M., Abramson A.L., et al. HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 65 (2004) 773-782
7. Khakoo S.I., and Carrington M. KIR and disease: A model system or system of models?. Immunol Rev 214 (2006) 186-201
8. Lanier L.L. NK cell recognition. Annu Rev Immunol 23 (2005) 225-274
9. Biron C.A., and Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13 (2001) 458-464
10. Phillips J.H., Gumperz J.E., Parham P., and Lanier L.L. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268 (1995) 403-405
11. Vilches C., and Parham P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20 (2002) 217-251
12. Rajalingam R. Killer cell immunoglobulin-like receptors influence the innate and adaptive immune responses. Iran. J Immunol 4 (2007) 61-78
13. Arase H., Mocarski E.S., Campbell A.E., Hill A.B., and Lanier L.L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296 (2002) 1323-1326
14. Smith H.R., Heusel J.W., Mehta I.K., Kim S., Dorner B.G., Naidenko O.V., et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A 99 (2002) 8826-8831
15. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 (2002) 429-434
16. Chewning J.H., Gudme C.N., Hsu K.C., Selvakumar A., and Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179 (2007) 854-868
17. Biassoni R., Pessino A., Malaspina A., Cantoni C., Bottino C., Sivori S., et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol 27 (1997) 3095-3099
18. Stewart C.A., Laugier-Anfossi F., Vely F., Saulquin X., Riedmuller J., Tisserant A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 102 (2005) 13224-13229
19. Wilson M.J., Torkar M., Haude A., Milne S., Jones T., Sheer D., et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A 97 (2000) 4778-4783
20. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 7 (1997) 753-763
21. Du Z., Gjertson D.W., Reed E.F., and Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics 59 (2007) 1-15
22. Lindeberg H., Oster S., Oxlund I., and Elbrond O. Laryngeal papillomas: Classification and course. Clin Otolaryngol Allied Sci 11 (1986) 423-429
23. Maran A., Amella C.A., Di Lorenzo T.P., Auborn K.J., Taichman L.B., and Steinberg B.M. Human papillomavirus type 11 transcripts are present at low abundance in latently infected respiratory tissues. Virology 212 (1995) 285-294
24. Abramson A.L., Shikowitz M.J., Mullooly V.M., Steinberg B.M., Amella C.A., and Rothstein H.R. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch Otolaryngol Head Neck Surg 118 (1992) 25-29
25. Steinberg B.M., Gallagher T., Stoler M., and Abramson A.L. Persistence and expression of human papillomavirus during interferon therapy. Arch Otolaryngol Head Neck Surg 114 (1988) 27-32
26. Kashima H.K., Lenventhal B., and Mounts P. Papilloma Study Group Scoring system to assess severity and course in recurrent respiratory papillomatosis. Papillomavirus: Molecular and clinical aspects (1985), Alan R. Liss, New York
27. Bonagura V.R., Siegal F.P., Abramson A.L., Santiago-Schwarz F., O'Reilly M.E., Shah K., et al. Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Clin Diagn Lab Immunol 1 (1994) 357-360
28. Luo L., Du Z., Sharma S.K., Cullen R., Spellman S., Reed E.F., et al. Chain-terminating natural mutations affect the function of activating KIR receptors 3DS1 and 2DS3. Immunogenetics 10 (2007) 779-792
29. Bonagura V.R., Cunningham-Rundles S., Edwards B.L., Ilowite N.T., Wedgwood J.F., and Valacer D.J. Common variable hypogammaglobulinemia, recurrent pneumocystis carinii pneumonia on intravenous gamma-globulin therapy, and natural killer deficiency. Clin Immunol Immunopathol 51 (1989) 216-231
30. Yokoyama W.M., and Scalzo A.A. Natural killer cell activation receptors in innate immunity to infection. Microbes Infect 4 (2002) 1513-1521
31. Lanier L.L. Natural killer cell receptor signaling. Curr Opin Immunol 15 (2003) 308-314
32. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
33. Carrington M., Wang S., Martin M.P., Gao X., Schiffman M., Cheng J., et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201 (2005) 1069-1075
34. Hildesheim A., and Wang S.S. Host and viral genetics and risk of cervical cancer: A review. Virus Res 89 (2002) 229-240
35. DeVoti J.A., Rosenthal D.W., Wu R., Abramson A.L., Steinberg B.M., and Bonagura V.R. Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: A paired microarray analysis. Mol Med 14 (2008) 608-617
36. Garcia C.A., Robinson J., Guethlein L.A., Parham P., Madrigal J.A., and Marsh S.G. Human KIR sequences 2003. Immunogenetics 55 (2003) 227-239
37. Yawata M., Yawata N., Draghi M., Little A.M., Partheniou F., and Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 203 (2006) 633-645
38. VandenBussche C.J., Dakshanamurthy S., Posch P.E., and Hurley C.K. A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain. J Immunol 177 (2006) 5347-5357
39. O'Connor G.M., Guinan K.J., Cunningham R.T., Middleton D., Parham P., and Gardiner C.M. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 178 (2007) 235-241
40. Valiante N.M., Uhrberg M., Shilling H.G., Lienert-Weidenbach K., Arnett K.L., D'Andrea A., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7 (1997) 739-751
41. + T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology 111 (2004) 100-106
42. Huang K.H., Loutfy M.R., Tsoukas C.M., and Bernard N.F. Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption. BMC Infect Dis 8 (2008) 59
43. + T cell subsets in chronic lymphocytic leukemia. J Immunol 158 (1997) 1482-1489
44. Chattopadhyay P.K., Betts M.R., Price D.A., Gostick E., Horton H., Roederer M., et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: Expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 85 (2009) 88-97
45. Denis L., Sivula J., Gourraud P.A., Kerdudou N., Chout R., Ricard C., et al. Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion. Tissue Antigens 66 (2005) 267-276
46. Norman P.J., Carrington C.V., Byng M., Maxwell L.D., Curran M.D., Stephens H.A., et al. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and south Asian populations. Genes Immun 3 (2002) 86-95
47. Single R.M., Martin M.P., Gao X., Meyer D., Yeager M., Kidd J.R., et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 39 (2007) 1114-1119
48. Stanley M.A. Human papillomavirus vaccines. Rev Med Virol 16 (2006) 139-149
49. Parikh S., Brennan P., and Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 105 (2003) 687-691
50. Leung R., Hawkes M., and Campisi P. Severity of juvenile-onset recurrent respiratory papillomatosis is not associated with socioeconomic status in a setting of universal health care. Int J Pediatr Otorhinolaryngol 71 (2007) 965-972